Introduction
============

Breast cancer is a type of most commonly highly metastatic malignant tumor among females.[@b1-ott-9-3443] Neoadjuvant chemotherapy was first used as induced chemotherapy or primary chemotherapy to treat locally advanced and inoperable breast cancer. Patients with breast cancer with pathological complete response (pCR) after neoadjuvant chemotherapy were able to achieve better overall survival rate.[@b2-ott-9-3443],[@b3-ott-9-3443] Therefore, pursuing the pCR becomes the primary goal in neoadjuvant chemotherapy.

Neoadjuvant chemotherapy can be used to evaluate the therapeutic effect of tumors, and the evaluation of neoadjuvant chemotherapy has advantages in providing prognosis and adjusting treatment strategy compared to other treatments. Therefore, with the development of research in neoadjuvant chemotherapy, its application has expanded from locally advanced to early and medium stage in breast cancer.[@b4-ott-9-3443] Neoadjuvant chemotherapy is the best in vivo chemosensitivity test because an effective follow-up plan can be made according to the reaction of tumor during chemotherapy treatment, and it is an important method of achieving individualized treatment in operable breast cancer.[@b5-ott-9-3443],[@b6-ott-9-3443] The advantage of neoadjuvant chemotherapy in operable breast cancer before operation can not only decrease the size of large tumors and clinical staging but also narrow the area of operative surgical resection and kill small metastasized micrometastases prior to surgery. An objective evaluation of resistance to chemotherapy in cancer and prognosis by clinical and pathological response is another advantage.[@b7-ott-9-3443] The pCR rate can be mainly used to predict the long-term outcomes of neoadjuvant chemotherapy and also as a surrogate end point in clinical trials.[@b8-ott-9-3443]

The best preoperative treatment should achieve a high pCR rate by neoadjuvant chemotherapy. The effect of the chemotherapy regimen, capecitabine/epirubicin/cyclophosphamide (XEC), as a neoadjuvant chemotherapy regimen has been reported to be better than that of 5-fluorouracil (5-FU)/epirubicin/cyclophosphamide (FEC), with a good tolerance; thus, it is advisable to use XEC instead of FEC during neoadjuvant or adjuvant chemotherapy treatment.[@b9-ott-9-3443] Lee et al[@b10-ott-9-3443] claimed that the efficacy of capecitabine (Xeloda^®^, F. Hoffmann La-Roche, Basel, Switzerland)/docetaxel (Taxotere^®^, Sanofi-Aventis, Paris, France) (XT) neoadjuvant chemotherapy was better than doxorubicin/cyclophosphamide (AC), because the pCR rate of the former was significantly improved and treatment-related G3/4 adverse events were relatively lower. Other data[@b11-ott-9-3443],[@b22-ott-9-3443] proved that capecitabine which treated patients with metastatic breast cancer was a valid single reagent and well tolerated. A meta-analysis also reported that capecitabine should be used in neoadjuvant chemotherapy, and treatment with XT was the first-line chemotherapy regimen with an effective rate of 42%.[@b13-ott-9-3443] Another meta-analysis also reported that treatment with XT can effectively improve the efficacy of adjuvant chemotherapy and is highly likely to become a new adjuvant chemotherapy regimen.[@b14-ott-9-3443]

The primary objective of this study was to compare the tumor pCR rate achieved with four 3-weekly cycles of XEC vs FEC when used as neoadjuvant chemotherapy for patients with axillary lymph node (LN)-positive stage II/III and operable breast cancer.

Patients and methods
====================

Study design
------------

This was a randomized, open-label, single-center clinical trial comparing XEC with FEC as a neoadjuvant chemotherapy for patients with axillary LN-positive stage II/III and operable breast cancer. All the patients provided written informed consent before enrollment. Furthermore, all the procedures performed in this study involving human participants followed the ethical standards of the Medical ethics committee of the Affiliated Cancer Hospital of Guangxi Medical University who approved the study and followed the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

The trial profile is shown in [Figure 1](#f1-ott-9-3443){ref-type="fig"}. Patients were randomized to one of two treatment arms: capecitabine (Xeloda^®^; Shanghai Roche Pharmaceuticals Ltd., Shanghai, People's Republic of China) 1,000 mg/m^2^ orally twice daily on days 1--14, plus epirubicin (Pfizer, Inc., New York, NY, USA) 100 mg/m^2^ infusion on day 1, plus cyclophosphamide (Endoxan^®^; Baxter Oncology GmbH, Halle, Germany) 500 mg/m^2^ infusion on day 1 every 3 weeks for four cycles, or 5-FU (Shanghai Xudong Haipu Pharmaceutical Co. Ltd., Shanghai, People's Republic of China) 500 mg/m^2^ infusion on day 1, plus epirubicin 100 mg/m^2^ infusion on day 1, plus cyclophosphamide 500 mg/m^2^ infusion on day 1 every 3 weeks for four cycles before surgery. The first assessment of curative effect was performed within 24--48 hours before the third cycle of chemotherapy when the second cycle was over, and the second assessment was performed within 24--48 hours after the fourth cycle. If the evaluation was considered invalid, then the patients were categorized as invalid group and the others underwent surgery after the fourth cycle of neoadjuvant chemotherapy and then crossed over to receive the other treatment regimens as adjuvant therapy. In the XEC arm, four-cycle adjuvant chemotherapy of XT was given: capecitabine 1,000 mg/m^2^ orally twice daily on days 1--14, plus docetaxel (Jiangsu Hengrui Medicine Co. Ltd., Lianyungang, People's Republic of China) 75 mg/m^2^ infusion on day 1 every 3 weeks. In the FEC arm, four-cycle adjuvant chemotherapy of T was given: docetaxel 75 mg/m^2^ infusion on day 1 every 3 weeks. All patients positive for human epidermal growth factor receptor 2 (HER2) were not using trastuzumab while receiving adjuvant chemotherapy because it might increase the cardiac toxicity of chemotherapy drugs. Upon completion of the adjuvant chemotherapy, all patients received radiotherapy and were concurrently treated with tamoxifen or letrozole when hormone receptor (HR) was positive.

Eligibility criteria
--------------------

To be included in the study, patients should have biopsy-proven, newly diagnosed stage II/III, and operable breast cancer with axillary LN involved. Operable breast cancer was defined as a tumor with a diameter of \>1 cm diagnosed by ultrasonography or magnetic resonance imaging (MRI). The axillary LN positivity was determined by fine-needle aspiration cytology of axillary LN. Further, the eligibility criteria included patients aged 18--70 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 and adequate hematologic (absolute neutrophil count ≥1,500/mm^3^, platelet count ≥10,000/mm^3^, hemoglobin ≥10 g/dL), renal (serum creatinine ≤1.5 mg/dL), cardiac (confirmed by normal or nonspecific ECG or multigated acquisition scan taken within 1 month of enrollment), and hepatic (total bilirubin ≤1.5 mg/dL, aspartate aminotransferase, alanine transaminase, alkaline phosphatase ≤2.5× upper normal limit) functions. Patients were excluded if they had undergone prior surgery, hormonal treatment, chemotherapy, or radiotherapy, or had a history of cancer except for in situ uterine cervical cancer or non-melanotic skin cancer, any distant metastasis, or any serious concomitant systemic disorder.

Patient evaluations
-------------------

The three-dimensional size of the primary breast tumor was measured by physical examination, ultrasound, and molybdenum target or MRI. These measuring methods started within 1--2 days before the first cycle of neoadjuvant chemotherapy, before the third cycle, and after the fourth cycle.

Clinical response was assessed using the response evaluation criteria in solid tumors[@b15-ott-9-3443] and was categorized into invalid, partial response, clinical complete response (cCR), and pCR. In this study, pCR was defined such that invasive carcinoma was not found in both primary site and axillary node; however, pCR was considered if the ductal carcinoma remained in situ in the primary site.[@b16-ott-9-3443]

Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0.

Statistical methods
-------------------

The primary objective of this study was to compare pCR rates between the XEC and FEC groups. Chi-square test was used in the comparison of clinical and pathological response rates and toxicities in the two treatment groups, while Fisher's exact test was used when the cell expectation was less than six. Breslow--Day test for homogeneity was performed to determine whether significant treatment by subgroup interactions existed with respect to pCR. All statistical analyses were performed using SPSS Version 20.0 (IBM Corporation, Armonk, NY, USA) with significance determined at *P*\<0.05.

Results
=======

Patient characteristics
-----------------------

A total of 137 patients were enrolled in this study between January 2011 and December 2013. Of these, 131 patients had clinical and radiological evaluation of response and completed surgery and were randomly assigned to the XEC (n=61) and FEC (n=70) groups. The reasons why the six subjects were withdrawn from the study were as follows: three patients refused further chemotherapy or surgery after the third cycle of FEC, one patient refused surgery after the fourth cycle of FEC, and two patients refused any further therapy after the first cycle of XEC.

Patients' baseline characteristics were balanced between the two treatment arms ([Table 1](#t1-ott-9-3443){ref-type="table"}). Patients in each treatment arm were well matched for age, ECOG performance status, clinical T-stage, pathological pattern, clinical N-stage, estrogen receptor, progesterone receptor, and HER2 status. Invasive ductal carcinoma (n=47, 77%) was the most common pathological pattern. All patients had an ECOG performance status of 0 or 1. HR and HER2 were positive in 64% (XEC vs FEC: 64% vs 64%) and 29% (XEC vs FEC: 28% vs 30%) of patients, respectively.

Efficacy
--------

Of the 131 patients evaluable for response, one patient in the XEC arm and two patients in the FEC arm did not complete treatment due to tumor progression or stable disease and received alternative chemotherapy prior to surgery. Treatment with XEC led to an increased rate of pCR (18% vs 6%, *P*=0.027), cCR (20% vs 7%, *P*=0.033), and objective remission rate (ORR; 87% vs 73%, *P*=0.048) compared with FEC ([Table 2](#t2-ott-9-3443){ref-type="table"}). No patient progressed in the XEC arm, whereas eight patients progressed in the FEC arm (13%, *P*=0.004).

Tumor ORRs were not significantly different among the various molecular types of breast cancer between the two arms (*P*\>0.05) as shown in [Table 3](#t3-ott-9-3443){ref-type="table"}. The ORR was greater in XEC than in FEC in triple-negative breast cancer (TNBC) without statistical significance (92% vs 73%, *P*=0.571).

An exploratory analysis of pCR rate according to major subgroups (age, T-stage, N-stage, HR status, HER2 status, molecular type, and clinical response) was performed ([Table 4](#t4-ott-9-3443){ref-type="table"}). Although the subset analysis might not have enough power to detect the differences, XEC appeared more effective than FEC, particularly in patients with TNBC (83% vs 22%; *P*=0.009; interaction *P*=0.028).

Safety
------

Safety was assessed in all 131 patients. The tolerance in XEC and FEC regimens was good ([Table 5](#t5-ott-9-3443){ref-type="table"}). In terms of 3/4 grade treatment-related clinical adverse events, there were more cases of hand-foot syndrome (HFS; 57% vs 11%, *P*\<0.001) and 3/4 grade nausea/vomiting/diarrhea (30% vs 14%, *P*=0.034) but less cases of phlebitis (3% vs 14%, *P*=0.035) in XEC compared with FEC. The incidence of 3/4 grade leukopenia (18% vs 16%, *P*=0.723), arthralgia/myalgia (5% vs 8%, *P*=0.502), alopecia (85% vs 89%, *P*=0.572), and 3/4 grade mucositis (8% vs 10%, *P*=0.721) was lower in XEC than in FEC, but the difference between the two groups was not statistically significant.

XT and T adjuvant chemotherapy regimens were well tolerated ([Table 6](#t6-ott-9-3443){ref-type="table"}). In terms of 3/4 grade treatment-related clinical adverse events, there were more cases of HFS (16% vs 0%, *P*\<0.001) in XT compared to T, and the treatment-related 3/4 grade adverse events occurred in 28% and 17% of patients receiving XT and T, respectively. XT and T were associated with a similar rate of 3/4 grade leukopenia (20% vs 14%, *P*=0.411), 3/4 grade nausea/vomiting/diarrhea (7% vs 1%, *P*=0.126), 3/4 grade mucositis (3% vs 1%, *P*=0.922), and alopecia (100% vs 99%, *P*=1.000).

Discussion
==========

The incidence of breast cancer has a rising tendency in developed cities in the People's Republic of China and becomes the first morbidity of malignant tumor among females.[@b17-ott-9-3443] The treatment is conventional surgery assisted with chemotherapy and radiotherapy, while distant metastasis and local relapse are the main reasons for mortality in breast carcinoma.

Neoadjuvant chemotherapy before surgery is one of the main treatments for locally advanced breast cancer. It not only narrows the primary lesion and regional LNs, degrades clinical staging, increases the chances in patients who could not be operated before, and improves the resection rate and the breast conserving rate but also controls subclinical lesions effectively, reduces tumor loading, and improves the prognosis. Furthermore, it could reduce the chances of distant metastasis by destroying distantly potential micrometastasis and provide evidence for sequential treatment through judging the sensitivity of tumors to chemotherapy.[@b18-ott-9-3443],[@b19-ott-9-3443] Currently, neoadjuvant chemotherapy has become a standard treatment for invasive breast cancer in stage II/III, but there is no unified standard in the specific treatment including cyclophosphamide/methotrexate/5-FU, 5-FU/adriamycin/cyclophosphamide, FEC, and docetaxel/doxorubicin/cyclophosphamide.[@b20-ott-9-3443],[@b21-ott-9-3443]

Neoadjuvant chemotherapy has provided an opportunity for studying the biological effects of systemic treatment in breast cancer and can be used to choose effective index for predicting the prognosis in clinical settings. Early systemic chemotherapy can induce apoptosis of tumor cells and reduce the metastasis rate in surgery.[@b22-ott-9-3443] The pathological response in the primary tumor after neoadjuvant chemotherapy is closely related to prognosis. Patients with pCR have an 86% 5-year survival rate and achieve an obvious survival benefit. Therefore, we can evaluate the effect of chemotherapy through pathological response condition of the primary tumor and predict the prognosis.[@b18-ott-9-3443],[@b20-ott-9-3443],[@b23-ott-9-3443],[@b24-ott-9-3443] Patients who responded well to neoadjuvant chemotherapy especially those with pCR, have a significantly improved disease-free survival rate.[@b25-ott-9-3443]

Capecitabine, as an antimetabolite, is a new-generation oral derivative of FU. After ingestion, it is rapidly nearly completely absorbed as an active compound in the gastrointestinal tract and is converted into 5-FU via a three-step enzymatic pathway.[@b26-ott-9-3443],[@b27-ott-9-3443] After two intermediate steps involving carboxylesterase in the liver and cytidine deaminase in the liver and/or tumor tissue, the final metabolite is converted into 5-FU by thymidine phosphorylase. Thymidine phosphorylase as the last enzyme in the activation of capecitabine has a higher concentration in malignant cells compared to healthy tissue, especially in breast cancer and gastric carcinoma causing DNA dyssynthesis in cancer tissue to achieve an antitumor effect, thus having selective and targeted anti-tumor effect.[@b28-ott-9-3443] Therefore, cancer tissue can convert more capecitabine into 5-FU, with less concentration in healthy tissue, so that 5-FU does not injure the healthy tissue and has less toxic and side effects. In conclusion, capecitabine is an oral chemotherapy drug with less toxicity and has a unique advantage in the treatment of breast cancer.

Patients with stage II/III breast cancer were treated prior to surgery by neoadjuvant chemotherapy, including treatment regimens XEC and FEC where both were compared for efficacy and adverse events in this study. It was concluded from the results that compared to the FEC arm, XEC significantly increased both the tumor pCR rate (18% vs 6%, *P*=0.027) and the clinical response rate (87% vs 73%, *P*=0.048). A large-scale, multiple-center clinical research reported that patients with primary or metastatic breast cancer who could not be treated with anthracycline- and/or taxol-containing regimens can be treated with capecitabine. The effective rate of single-drug first-line treatment was found to be 15%--37%, and the median progression-free survival was from 3 to 5 months.[@b29-ott-9-3443] In the study by Kamal et al,[@b30-ott-9-3443] 257 patients with metastatic breast cancer were treated with capecitabine or taxol. The results showed that the overall survival rate and tumor specificity in patients treated with capecitabine or taxol were similar, and there was no significant difference in the survival benefit. In addition, the results from a multiple-center, randomized Phase III clinical trial showed that the effect of capecitabine was as good as the combination of vinorelbine plus gemcitabine, when compared between these drugs in patients who were treated ineffectively with anthracycline- and/or taxol-containing regimens.[@b31-ott-9-3443] Therefore, capecitabine played an important role in both single drug and combination therapy. Capecitabine monotherapy or capecitabine-containing regimens can be used not only as first-line treatment in advanced breast cancer but also as second- or third-line treatment in locally advanced breast cancer due to its good tolerance to side effects.[@b32-ott-9-3443]--[@b35-ott-9-3443] After success with combination therapy, sequential treatment until single-drug maintenance could prolong the survival time in advanced breast cancer patients.

One research[@b36-ott-9-3443] showed that TNBC was more sensitive to capecitabine and could achieve better pCR and cCR as neoadjuvant chemotherapy compared to non-TNBC. Other studies[@b37-ott-9-3443],[@b38-ott-9-3443] suggested that HR-positive tumors show resistance to chemotherapeutic drugs and were difficult to achieve pCR. In this study, the fact that 92% of TNBC achieved ORR in XEC while only 73% in FEC implied that treatment with XEC would have better curative effect to TNBC than FEC. Since there was no statistically significant difference, the result may change if the number of subjects was increased. In addition, XEC achieved more tumor pCR (ten patients, 83%) compared with FEC (two patients, 22%) in TNBC (*P*=0.009; interaction *P*=0.028). At the same time, XEC had a trend toward increased pCR in patients with HR negative and HER2 negative/unknown. Similarly, due to small sample, the result may change after increasing the number of subjects, although there was no statistically significant difference.

In addition to superior efficacy, the tolerability of XEC was also compared to that of FEC. From the comparison of adverse events, the incidence rate of HFS in the XEC arm was higher (57% vs 11%, *P*\<0.001) compared to the FEC arm. Several studies showed that the incidence rate of HFS in capecitabine-containing chemotherapy regimens was higher because of the characteristics of the drug, which was consistent with the results in this study.[@b39-ott-9-3443],[@b40-ott-9-3443] Severe HFS may lead to reduction in drug dosage; therefore, it is important to prevent and reduce the incidence rate and degree of this syndrome, and it is known that vitamin B6 can relieve the symptom of HFS caused by 5-FU. In this study, it is reported that oral capecitabine with a large dose of vitamin B6 (300 mg/d) can reduce the incidence rate and symptom of HFS. In addition, a retrospective study suggested that cyclooxygenase-specific inhibitor might have the same effect as the combination of capecitabine and vitamin B6, as well.[@b41-ott-9-3443] There were more patients with 3/4 grade nausea/vomiting/diarrhea in the XEC arm than in the FEC arm (30% vs 14%; *P*=0.034), because capecitabine was absorbed in the gastrointestinal tract and needs to be taken orally for 2 weeks.

The side effects such as phlebitis, arthralgia/myalgia, alopecia, leukopenia, and 3/4 grade mucositis were lower in XEC than in FEC. Among them, there was a statistically significant difference in phlebitis. XT and T adjuvant chemotherapy regimens were well tolerated: treatment-related 3/4 grade adverse events occurred in 28% and 17% of patients receiving XT and T, without statistical significance, respectively. This indicated that the XEC followed by XT regimen can be safely implemented because of less side effects and toxicity.

Conclusion
==========

This study showed that the XEC regimen was effective and had similar curative effect compared to the FEC regimen. Due to its good tolerability and low incidence and severity of preventable adverse events, XEC regimen should be promoted and implemented in clinical practice.
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###### 

Patient characteristics

  Characteristics              XEC (n=61)    FEC (n=70)    *P*-value*[\*](#tfn1-ott-9-3443){ref-type="table-fn"}*
  ---------------------------- ------------- ------------- --------------------------------------------------------
  Number of patients                                       
   Enrolled                    63            74            0.689
   Dropouts                    2             4             
  Age (years)                                              
   Median (range)              43 (19--68)   42 (21--69)   0.215
  ECOG performance status                                  
   0                           39            44            0.898
   1                           22            26            
  Clinical T-stage                                         
    ≥5 cm                      35            39            0.848
   \<5 cm                      26            31            
  Pathological pattern                                     
   Invasive ductal carcinoma   47            53            0.570
   Mucinous carcinoma          2             1             
   Cribriform carcinoma        1             0             
  Clinical N-stage                                         
   N1                          28            35            0.842
   N2                          23            23            
   N3                          10            12            
  HR                                                       
   Positive                    39            45            0.967
   Negative                    22            25            
  HER2                                                     
   Positive                    17            21            0.814
   Negative                    41            44            
   Unknown                     3             5             
  Molecular type                                           
   Triple negative             12            11            0.553
   Non-triple negative         49            59            

**Notes:**

*P*-value by chi-square test or Fisher's exact test when the cell expectation was less than six; for comparison of age distribution 2 sample, *t*-test was used. Her-2(+)meant it was positive in FISH or CISH test or (+++) in ICH test according to NCCN in 2011. In 2010, guidance for investigations of ER and PR in breast cancer was developed by ASCO and CAP where professors recommended that the positive criteria of ER and PR were ≥1% of positive nuclear staining.

**Abbreviations:** ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; CISH, chromogenic in situ hybridization; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; FEC, 5-FU/epirubicin/cyclophosphamide; 5-FU, 5-fluorouracil; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; ICH, immunohistochemistry; NCCN, National Comprehensive Cancer Network; PR, progesterone receptor; XEC, capecitabine/epirubicin/cyclophosphamide.

###### 

Pathological and clinical tumor response

  Variables             XEC (n=61) (%)   FEC (n=70) (%)   *P*-value[\*](#tfn3-ott-9-3443){ref-type="table-fn"}
  --------------------- ---------------- ---------------- ------------------------------------------------------
  pCR in tumor          11 (18)          4 (6)            0.027
  ORR                   53 (87)          51 (73)          0.048
  cCR                   12 (20)          5 (7)            0.033
  Partial response      41 (67)          46 (66)          0.865
  Stable disease        8 (13)           10 (14)          0.846
  Progressive disease   0 (0)            9 (13)           0.004

**Note:**

*P*-value by chi-square test or Fisher's exact test when the cell expectation was \<6.

**Abbreviations:** cCR, clinical complete response; FEC, 5-FU/epirubicin/cyclophosphamide; 5-FU, 5-fluorouracil; ORR, objective remission rate; pCR, pathological complete response; XEC, capecitabine/epirubicin/cyclophosphamide.

###### 

Tumor ORRs between the two arms

  Variables             XEC (n=61) (%)   FEC (n=70) (%)   *P*-value[\*](#tfn5-ott-9-3443){ref-type="table-fn"}
  --------------------- ---------------- ---------------- ------------------------------------------------------
  Luminal-A             8 (89)           10 (77)          0.616
  Luminal-B                                               
   HER2 negative        20 (87)          18 (72)          0.292
   HER2 positive        6 (86)           5 (71)           1.000
  HER2 overexpression   8 (80)           10 (71)          0.659
  Triple negative       11 (92)          8 (73)           0.571

**Note:**

*P*-value by chi-square test or Fisher's exact test when the cell expectation was less than six.

**Abbreviations:** FEC, 5-FU/epirubicin/cyclophosphamide; 5-FU, 5-fluorouracil; HER2, human epidermal growth factor receptor 2; ORR, objective remission rate; XEC, capecitabine/epirubicin/cyclophosphamide.

###### 

Tumor pCR rates in patient subgroups

  Subset                 XEC (%)   FEC (%)   *P*-value[\*](#tfn7-ott-9-3443){ref-type="table-fn"}   Interaction *P*
  ---------------------- --------- --------- ------------------------------------------------------ -----------------
  Age (years)                                                                                       
   \<50                  4 (10)    1 (2)     0.184                                                  0.873
    ≥50                  7 (37)    3 (13)    0.143                                                  
  T-stage                                                                                           
   \<5 cm                7 (27)    3 (10)    0.160                                                  0.795
    ≥5 cm                4 (11)    1 (3)     0.183                                                  
  N-stage                                                                                           
   N1                    6 (21)    3 (9)     0.170                                                  0.583
   N2/N3                 5 (15)    1 (3)     0.101                                                  
  HR                                                                                                
   Positive              4 (10)    2 (4)     0.409                                                  0.529
   Negative              7 (32)    2 (8)     0.063                                                  
  HER2                                                                                              
   Positive              3 (18)    1 (5)     0.307                                                  0.870
   Negative/unknown      8 (18)    3 (6)     0.072                                                  
  Molecular type                                                                                    
   Triple negative       10 (83)   2 (22)    0.009                                                  0.028
   Non-triple negative   1 (2)     2 (3)     1.000                                                  
  Clinical response                                                                                 
   CR                    5 (42)    1 (20)    0.600                                                  0.995
   PR/SD/PD              6 (12)    3 (5)     0.307                                                  

**Note:**

*P*-value by chi-square test or Fisher's exact test when the cell expectation was less than six.

**Abbreviations:** CR, complete response; FEC, 5-FU/epirubicin/cyclophosphamide; 5-FU, 5-fluorouracil; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; pCR, pathological complete response; PD, progressive disease; PR, partial response; SD, stable disease; XEC, capecitabine/epirubicin/cyclophosphamide.

###### 

Treatment-related clinical adverse events in XEC and FEC arms

  ---------------------------------------------------------------------------------------------------------------------------
  Adverse Event                              XEC\         FEC\         *P*-value[\*](#tfn9-ott-9-3443){ref-type="table-fn"}
                                             (n=61) (%)   (n=70) (%)   
  ------------------------------------------ ------------ ------------ ------------------------------------------------------
  3/4 grade adverse events                   34 (56)      28 (40)      0.072

  3/4 grade leukopenia                       11 (18)      11 (16)      0.723

  3/4 grade nausea, vomiting, and diarrhea   18 (30)      10 (14)      0.034

  3/4 grade mucositis                        5 (8)        7 (10)       0.721

  HFS                                        35 (57)      8 (11)       0.000

  Phlebitis                                  2 (3)        10 (14)      0.035

  Arthralgia and myalgia                     3 (5)        6 (8)        0.502

  Alopecia                                   52 (85)      62 (89)      0.572
  ---------------------------------------------------------------------------------------------------------------------------

**Note:**

*P*-value by chi-square test or Fisher's exact test when the cell expectation was less than six.

**Abbreviations:** FEC, 5-FU/epirubicin/cyclophosphamide; 5-FU, 5-fluorouracil; HFS, hand-foot syndrome; XEC, capecitabine/epirubicin/cyclophosphamide.

###### 

Treatment-related clinical adverse events in XT and T arms

  ----------------------------------------------------------------------------------------------------------------------------
  Adverse Event                              XT\          T\           *P*-value[\*](#tfn11-ott-9-3443){ref-type="table-fn"}
                                             (n=61) (%)   (n=70) (%)   
  ------------------------------------------ ------------ ------------ -------------------------------------------------------
  3/4 grade adverse events                   17 (28)      12 (17)      0.140

  3/4 grade leukopenia                       12 (20)      10 (14)      0.411

  3/4 grade nausea, vomiting, and diarrhea   4 (7)        1 (1)        0.126

  3/4 grade mucositis                        1 (3)        1 (1)        0.922

  HFS                                        10 (16)      0 (0)        0.000

  Alopecia                                   61 (100)     69 (99)      1.000
  ----------------------------------------------------------------------------------------------------------------------------

**Note:**

*P*-value by chi-square test or Fisher's exact test when the cell expectation was less than six.

**Abbreviations:** HFS, hand-foot syndrome; XT, capecitabine/docetaxel; T, docetaxel.
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